{"id":49070,"date":"2022-10-03T12:03:14","date_gmt":"2022-10-03T10:03:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/"},"modified":"2022-10-03T12:03:14","modified_gmt":"2022-10-03T10:03:14","slug":"seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/","title":{"rendered":"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study"},"content":{"rendered":"
\n

PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I\/II clinical study utilizing Seneca Valley Virus (\u201cSVV-001\u201d) in combination with a checkpoint inhibitor. This Phase I\/II study with SVV-001 is in patients that are TEM8 positive and SVV-001 permissive with neuroendocrine tumors or neuroendocrine carcinomas. The study should begin enrollment early in 2023.\n<\/p>\n

<\/a><\/p>\n

\nAbout Seneca Therapeutics<\/span><\/b>\n<\/p>\n

\nSeneca Therapeutics was founded to capitalize on the profound tumor specificity of SVV and further the development of SVV-001 in several upcoming clinical trials and the creation and testing of armed derivatives selectively expressing gene product(s) that are inserted into the genome of SVV-001 that create additional anti-tumor effects.\n<\/p>\n

\nForward-Looking Statements<\/span><\/b>\n<\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d concerning the development of Seneca Therapeutics products, the potential benefits and attributes of those products, and the company\u2019s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Seneca Therapeutics undertakes no obligation to update any forward-looking statements for any reason.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nPaul Hallenbeck
\n
CSO and President
\n
phallenbeck@senecatherapeutics.com<\/a>\n<\/p>\n

\nJames Hussey
\n
CEO
\n
jhussey@senecatherapeutics.com<\/a>\n<\/p>\n

\nwww.senecatherapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I\/II clinical study utilizing Seneca Valley Virus (\u201cSVV-001\u201d) in combination with a checkpoint inhibitor. This Phase I\/II study with SVV-001 is in patients … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49070","6":"format-standard","7":"category-industry"},"yoast_head":"\nSeneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I\/II clinical study utilizing Seneca Valley Virus (\u201cSVV-001\u201d) in combination with a checkpoint inhibitor. This Phase I\/II study with SVV-001 is in patients ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-03T10:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221003005089\/en\/1588269\/21\/Seneca_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\\\/II Clinical Study\",\"datePublished\":\"2022-10-03T10:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/\"},\"wordCount\":246,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005089\\\/en\\\/1588269\\\/21\\\/Seneca_Therapeutics_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/\",\"name\":\"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\\\/II Clinical Study - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005089\\\/en\\\/1588269\\\/21\\\/Seneca_Therapeutics_Logo.jpg\",\"datePublished\":\"2022-10-03T10:03:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005089\\\/en\\\/1588269\\\/21\\\/Seneca_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221003005089\\\/en\\\/1588269\\\/21\\\/Seneca_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\\\/II Clinical Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/","og_locale":"en_US","og_type":"article","og_title":"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study - Pharma Trend","og_description":"PHILADELPHIA–(BUSINESS WIRE)–Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of novel immunotherapies for difficult to treat solid cancers announced today it had received FDA clearance to begin a Phase I\/II clinical study utilizing Seneca Valley Virus (\u201cSVV-001\u201d) in combination with a checkpoint inhibitor. This Phase I\/II study with SVV-001 is in patients ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-03T10:03:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221003005089\/en\/1588269\/21\/Seneca_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study","datePublished":"2022-10-03T10:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/"},"wordCount":246,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221003005089\/en\/1588269\/21\/Seneca_Therapeutics_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/","url":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/","name":"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221003005089\/en\/1588269\/21\/Seneca_Therapeutics_Logo.jpg","datePublished":"2022-10-03T10:03:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221003005089\/en\/1588269\/21\/Seneca_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221003005089\/en\/1588269\/21\/Seneca_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/seneca-therapeutics-receives-fda-clearance-to-begin-svv-001-phase-i-ii-clinical-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Seneca Therapeutics Receives FDA Clearance to Begin SVV-001 Phase I\/II Clinical Study"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49070"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49070\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}